Immuno-Biological Laboratories Co., Ltd. Logo

Immuno-Biological Laboratories Co., Ltd.

Develops and supplies immunological reagents and diagnostics for research and drug discovery.

4570 | T

Overview

Corporate Details

ISIN(s):
JP3921300004
LEI:
Country:
Japan
Address:
藤岡市中字東田1091番地1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Immuno-Biological Laboratories Co., Ltd. (IBL) is a research-driven company that develops, manufactures, and supplies immunological research reagents and diagnostics. The company's portfolio includes ELISA kits, specialized antibodies, and cell culture-related products. IBL focuses on key therapeutic areas such as aging, neurodegenerative disorders, kidney diseases, inflammatory diseases, and glucose/lipid metabolism. A notable offering is the LipoSEARCH® lipoprotein analyzing system, which utilizes patented Gel Permeation High-Performance Liquid Chromatography (GP-HPLC) technology. The company collaborates with pharmaceutical partners and research institutions to support drug discovery and the development of novel diagnostics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 01:09
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-14 01:07
Interim Report
半期報告書-第44期(2025/04/01-2026/03/31)
Japanese 173.9 KB
2025-06-27 06:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2025-06-27 02:05
Governance Information
内部統制報告書-第43期(2024/04/01-2025/03/31)
Japanese 25.4 KB
2025-06-27 02:04
Registration Form
確認書
Japanese 8.7 KB
2025-06-27 02:02
Annual Report
有価証券報告書-第43期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2024-11-14 01:04
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-11-14 01:02
Interim Report
半期報告書-第43期(2024/04/01-2025/03/31)
Japanese 180.6 KB
2024-06-26 03:44
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2024-06-26 03:41
Governance Information
内部統制報告書-第42期(2023/04/01-2024/03/31)
Japanese 23.7 KB
2024-06-26 03:40
Registration Form
確認書
Japanese 8.7 KB
2024-06-26 03:38
Registration Form
有価証券報告書-第42期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-14 01:10
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-14 01:07
Quarterly Report
四半期報告書-第42期第3四半期(2023/10/01-2023/12/31)
Japanese 161.4 KB
2023-11-14 01:02
Report Publication Announcement
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Immuno-Biological Laboratories Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Immuno-Biological Laboratories Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Immuno-Biological Laboratories Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.